Ligand validation:9F9E

LI1: 1-[2,6,10.14-TETRAMETHYL-HEXADECAN-16-YL]-2-[2,10,14-TRIMETHYLHEXADECAN-16-YL]GLYCEROL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
9F9E_LI1_A_301	11%	69%	0.136	0.806	0.62	0.59	-	-	0	0	13%	1
9F9E_LI1_A_304	7%	62%	0.155	0.743	0.7	0.75	-	-	0	0	27%	1
9F9E_LI1_A_302	5%	59%	0.155	0.696	0.66	0.89	-	-	0	0	31%	1
9F9E_LI1_A_313	5%	65%	0.158	0.705	0.67	0.69	-	-	0	0	18%	1
9F9E_LI1_A_303	4%	64%	0.14	0.662	0.67	0.7	-	-	0	0	18%	1
9F9E_LI1_A_315	4%	69%	0.148	0.677	0.63	0.58	-	-	0	0	13%	1
9F9E_LI1_A_312	4%	60%	0.167	0.668	0.66	0.87	-	-	0	0	27%	0.51
9F9E_LI1_A_306	3%	60%	0.176	0.652	0.71	0.82	-	-	0	0	29%	1
9F9E_LI1_A_305	3%	61%	0.177	0.634	0.68	0.81	-	-	0	0	29%	1
9F9E_LI1_A_314	1%	65%	0.18	0.55	0.68	0.66	-	-	0	0	18%	1
9F9E_LI1_A_311	1%	60%	0.189	0.518	0.69	0.83	-	-	0	0	29%	1
9F9J_LI1_A_301	70%	91%	0.038	0.979	0.16	0.39	-	-	0	0	31%	1
3T45_LI1_B_604	36%	62%	0.142	0.852	0.6	0.85	-	1	11	0	89%	1
2I20_LI1_A_613	34%	60%	0.121	0.929	0.48	1.04	-	1	2	1	29%	1
9F9I_LI1_A_316	31%	91%	0.075	0.897	0.31	0.25	-	-	0	0	13%	1
9F9D_LI1_A_305	29%	61%	0.08	0.861	0.7	0.79	-	-	0	0	29%	1
6G7I_LI1_A_305	27%	63%	0.09	0.884	0.72	0.68	-	-	1	0	18%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.